Αρχική World News Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and Helen...

Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and Helen Chen

July 27, 2018, by NCI Staff

NCI is funding an initiative to identify biomarkers that can predict which patients are most likely to respond to immunotherapy treatments.

Credit: National Cancer Institute

NCI is supporting a new network of research centers and a data center created to develop biomarkers for immunotherapy. The network consists of four Cancer Immune Monitoring and Analysis Centers (CIMACs) and a data storage center, the Cancer Immunologic Data Commons (CIDC).

In this interview, Magdalena Thurin, Ph.D., of the Cancer Diagnosis Program and Helen Chen, M.D., of the Cancer Therapy Evaluation Program, both in NCI’s Division of Cancer Treatment and Diagnosis, discuss the network and its goals.

What is the goal of the research network?

Dr. Thurin: The long-term goal is to identify molecular signatures or biomarkers that, in the future, doctors can use to identify patients with cancer who are likely to respond to immunotherapy.

Dr. Chen: Biomarkers identified as a result of this project could also be used to help investigate mechanisms of resistance to immunotherapy, which may guide the development of combination therapies that may overcome this resistance. In addition, biomarkers could be identified that help to monitor patients’ responses to treatment.  

How will the new network of laboratory centers and the data center achieve this goal?

Dr. Thurin: The four centers, or CIMACs, will use state-of-the-art technologies to perform a range of molecular and cell-based testing on biospecimens—such as blood and tumor samplesfrom patients enrolled in early-phase immunotherapy clinical trials—phase 1 and phase 2—that are funded by NCI. These test results and clinical information about patients will be stored in the CIDC, which researchers can then use in follow-up studies to identify potential biomarkers.

Dr. Chen: The four CIMACs will use standardized assays for analyzing biospecimens collected from these immunotherapy clinical trials. That will ensure that there is a uniformity in their work and the results they produce, and it will give us more statistical power and provide greater confidence in any potential biomarkers that are identified.

Can you explain how the CIMACs are set up?

Dr. Chen: Each of the four CIMACs—Dana-Farber Cancer Institute, Stanford University, MD Anderson Cancer Center, and Icahn School of Medicine at Mount Sinai—has a multidisciplinary team with expertise in immunology, clinical investigation, pathology, bioassays, and bioinformatics.

These teams will work closely with the clinical investigators who are leading the early-stage immunotherapy trials to design their biomarker studies, apply different assays for identifying potential biomarkers, and analyze the results.

Why are biomarkers of response to immunotherapy needed?

Dr. Chen: Currently, a minority of patients with cancer benefit from immunotherapies. But we don’t know why only some patients respond to immunotherapy, and we cannot reliably predict which patients will benefit from the therapy. Validated biomarkers could help guide treatment decisions for patients and doctors who are considering immunotherapy.

Dr. Thurin: In addition, to improve the effectiveness of immunotherapies, we need to develop a better understanding of how the immune system interacts with tumors, which can help us develop tools for selecting the appropriate patients for a specific immunotherapy or combination therapy.

Do any biomarkers exist that can help guide treatment decisions about immunotherapy?

Dr. Chen: In recent years, several potential biomarkers have emerged, such as levels of a protein called PD-L1 expressed on tumor cells and immune cells in the tumor microenvironment. Another biomarker is tumor mutational burden, which is an assessment of the number of genetic mutations in a tumor. But we still need biomarkers that are more precise.

What is the CIDC’s role?

Dr. Thurin: The CIDC is hosted at Dana-Farber Cancer Institute and has multiple functions. But its primary role is to collect the biomarker data generated at the four CIMACs and to provide a platform for integrating patients’ clinical data—such as age, prior treatments, response to treatment, side effects—with data on the biospecimens. Having all of this information in the CIDC will help other researchers explore the data for biomarkers.

The CIDC will also provide some of the informatics tools for the analyses of the data. In the future, the CIDC is expected to serve the cancer research community in a manner similar to NCI’s Genomic Data Commons.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...